- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
ICMR issues advisory on use of CBNAAT for Coronavirus testing, details
According to the advisory, any laboratory, already functional for SARS-CoV-2 testing by real-time PCR with appropriate BSL-2 setup, may start testing using Xpert Xpress SARS-CoV-2 without any further approval from the ICMR.
New DelhiL The Indian Council of Medical Research (ICMR), here on Monday, issued an advisory on use of cartridge-based nucleic acid amplification test (CBNAAT) using Cepheid's Xpert Xpress SARS-CoV-2 test.
It has invited applications from laboratories for use of this testing method. Any testing with the Cepheid's Xpert Xpress SARS-CoV-2 is done under the biosafety 2 level (BSL-2) conditions and with appropriate precautions.
The CBNAAT is a recently introduced polymerase chain raction-based (PCR) method for detection of mycobacterium tuberculosis.
The Xpert Xpress SARS-CoV-2 test is a rapid, real-time RT-PCR test aimed at the qualitative detection of nucleic acid from the SARS-CoV-2 in either nasopharyngeal, nasal, or mid-turbinate swab and/or nasal wash/aspirate specimens collected from individuals suspected of Covid-19 by their healthcare provider.
It's a FDA approved testing system for use under the emergency use authorisation (EUA) only.
According to the advisory, any laboratory, already functional for SARS-CoV-2 testing by real-time PCR with appropriate BSL-2 setup, may start testing using Xpert Xpress SARS-CoV-2 without any further approval from the ICMR.
However, the test results will have to be uploaded on the ICMR Covid-19 portal.
The ICMR said any new government laboratory seeking to initiate the CBNAAT must meet the minimum ICMR requirements such as availability of a BSL-2 level laboratory facility, including a molecular biology setup for virological diagnosis and a functioning and calibrated biosafety cabinet type 2A/2B in the laboratory, staff having experience in molecular virology, a robust institutional policy on biomedical waste management of human origin and well-defined arrangement for segregation and discarding of biomedical waste.
Private laboratories that intended the CBNAAT should have the National Accreditation Board for Testing & Calibration Laboratories (NABL) accreditation for molecular detection of RNA viruses either by the real-time PCR or the CBNAAT, the apex medical research body added.
Read also: Karnataka slashes Private lab coronavirus test rates to Rs 2,250
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.